NEU protein overexpression in benign, borderline, and malignant ovarian neoplasms.

No abstract is available for this paper.

• Publication year

  1992

• Venue

  Gynecologic Oncology

• Publication date

  1992-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/0090-8258(92)90051-JPMID 1347282
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The cytokine CSF-1 (M-CSF) expressed by endometrial carcinomas in vivo and in vitro, may also be a circulating tumor marker of neoplastic disease activity in endometrial carcinoma patients.

  1990cited by this paper
• c‐erbB‐2 oncogene expression in ovarian cancer

  1990cited by this paper
• Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer.

  1990cited by this paper
• Ovarian adenocarcinomas express fms-complementary transcripts and fms antigen, often with coexpression of CSF-1.

  1990cited by this paper
• Proto-oncogene abnormalities in human breast cancer: c-ERBB-2 amplification does not correlate with recurrence of disease.

  1989cited by this paper
• Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.

  1989cited by this paper
• Distribution of neu (c-erbB-2) protein in human skin.

  1989cited by this paper
• Oncogene expression in vivo by ovarian adenocarcinomas and mixed-mullerian tumors.

  1989cited by this paper
• Tamoxifen in combination with cytotoxic chemotherapy in advanced epithelial ovarian cancer. A prospective randomized trial

  1989cited by this paper
• Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer.

  1988cited by this paper
• Alterations to either c-erbB-2(neu) or c-myc proto-oncogenes in breast carcinomas correlate with poor short-term prognosis.

  1987cited by this paper
• Overexpression of the c-erbB-2 oncoprotein in human breast carcinomas: immunohistological assessment correlates with gene amplification.

  1987cited by this paper
• Immunohistochemical Evaluation of Pleural Mesothelioma and Pulmonary Adenocarcinoma: A Bi-institutional Study of 47 Cases

  1987cited by this paper
• Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

  1987cited by this paper
• The neu oncogene encodes an epidermal growth factor receptor-related protein

  1986cited by this paper
• Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor

  1986cited by this paper
• Localization of a novel v-erbB-related gene, c-erbB-2, on human chromosome 17 and its amplification in a gastric cancer cell line

  1986cited by this paper
• Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene.

  1985cited by this paper
• Tetracycline resistance determined by pBR322 is mediated by one polypeptide.

  1983cited by this paper
• Clear cell carcinoma of the ovary: A clinicopathologic study with review of the literature

  1981cited by this paper
• Advanced ovarian cancer: correlation of histologic grade with response to therapy and survival.

  1980cited by this paper
• Tumors of the ovary and maldeveloped gonads

  1979cited by this paper
• Construction and characterization of new cloning vehicles. II. A multipurpose cloning system.

  1977cited by this paper
• Carcinoma of the Ovary

  1966cited by this paper
• Calculation of survival rates for cancer.

  1950cited by this paper

• MULTIVARIATE ANALYSIS WITH EMPHASIS OF HER2/NEU EXPRESSION ON OVARIAN TUMORS IN A TERTIARY CARE HOSPITAL

  2025cites this paper
• Predicting Response to Anthracyclines in Ovarian Cancer

  2022cites this paper
• A study of her-2/ neu oncogene expression in benign and malignant ovarian tumors

  2020cites this paper
• The expression status of human epidermal growth factor receptor 2 in epithelial ovarian cancer in Ibadan, Nigeria

  2016cites this paper
• Role of Her-2 Neu As Prognostic Indicator in Surface Epithelial Tumors of Ovary

  2016cites this paper
• Part 2 : Distribution of HER 2 / neu overexpression and gene amplification by organ , tumor site and histology

  2014cites this paper
• A Comparative Study of HER-2/neu Oncogene in Benign and Malignant Ovarian Tumors

  2014cites this paper
• Effi cacy of Possum Scoring System in Predicting Mortality and Morbidity in Patients of Peritonitis Undergoing Laparotomy

  2014cites this paper
• HER2/neu: an increasingly important therapeutic target. Part 2: Distribution of HER2/neu overexpression and gene amplification by organ, tumor site and histology

  2014cites this paper
• Expresión de oncogenes, receptores hormonales esteroideos y marcadores de proliferación en el carcinoma endometrial

  2014cites this paper
• EGFR/HER-targeted therapeutics in ovarian cancer.

  2012cites this paper
• In-labeled KCCYSL peptide as an imaging probe for ErbB-2-expressing ovarian carcinomas.

  2009cites this paper
• Associations between ERBB2 amplification and progression-free survival and overall survival in advanced stage, suboptimally-resected epithelial ovarian cancers: a Gynecologic Oncology Group Study.

  2009cites this paper
• Clinical implications of the ErbB/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancer.

  2008cites this paper
• Chapter 20 – Genes and Cancer

  2007cites this paper
• Rapid Communication Neu Proto-oncogene Amplification and Expression in Ovarian Adenocarcinoma Cell Lines of in

  2007cites this paper
• N-ras EXPRESSION IN HEPATO- CELLULAR CARCINOMA

  2007cites this paper
• Lack of prognostic significance of HER-2/neu in early epithelial ovarian cancer.

  2007cites this paper
• Prognostic, predictive and therapeutic implications of HER2 in invasive epithelial ovarian cancer.

  2006cites this paper
• Conservative surgery for borderline ovarian tumors: a review.

  2006cites this paper
• Borderline ovarian tumours: Current concepts and management

  2005cites this paper
• Pathophysiological dynamics of human ovarian surface epithelial cells in epithelial ovarian carcinogenesis.

  2005cites this paper
• Chapter 28 – Molecular Biology and Molecular Genetics of Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

  2004cites this paper
• Overexpression of HER-2/neu is not a risk factor in ovarian clear cell adenocarcinoma.

  2004cites this paper
• TP53 status determines clinical significance of ERBB2 expression in ovarian cancer

  2004influential citation
• In vitro chemoresistance and biomarker profiles are unique for histologic subtypes of epithelial ovarian cancer.

  2004cites this paper
• HER-2 and cancer antigen 125 evaluation in ovarian borderline tumors by immunohistochemistry and fluorescence in situ hybridization

  2004cites this paper
• Adjuvant Treatment for Early-Stage Epithelial Ovarian Cancer

  2004cites this paper
• Prognostic factors in ovarian cancer: current evidence and future prospects

  2003cites this paper
• Specific keynote: chemoprevention of ovarian cancer: the journey begins.

  2003cites this paper
• c-erbB-2, p53, and nm23 proteins as prognostic factors in patients with epithelial ovarian carcinoma.

  2003cites this paper
• Molecular similarities between primary peritoneal and primary ovarian carcinomas

  2003cites this paper
• Proteins as Prognostic Factors in Patients with Epithelial Ovarian Carcinoma Snje

  2003cites this paper
• The Genetic Etiology of Sporadic Ovarian Cancer

  2003cites this paper
• GENES and CANCER

  2002cites this paper
• Borderline-Tumoren des Ovars

  2002cites this paper
• Clinical and molecular comparison between borderline serous ovarian tumors and advanced serous papillary ovarian carcinomas.

  2001cites this paper
• Serous tumors of low malignant potential of the ovary-molecular pathology: part 2

  2001cites this paper
• The growth factor receptors HER-2/neu and EGFR, their relationship, and their effects on the prognosis in early stage (FIGO I-II) epithelial ovarian carcinoma

  2000cites this paper
• Ovarian serous borderline tumors: a critical review of the literature with emphasis on prognostic indicators.

  2000cites this paper
• Expression and Function of Egf-Related Peptides and Their Receptors in Gynecological Cancer - From Basic Science to Therapy?

  2000cites this paper
• Epidermal Growth Factor-Related Peptides in Endocrine Neoplasias

  2000cites this paper
• Clinical Use of Serum c-erbB-2 in Patients with Ovarian Masses

  1999cites this paper
• Prevention of ovarian cancer.

  1999cites this paper
• c-erbB-2 oncoprotein assay in ovarian carcinoma and its clinical correlation with prognostic factors.

  1998cites this paper
• Borderline Tumors of the Ovary: A Clinico‐Pathologic and Immunohistochemical Study of 54 Cases

  1998cites this paper
• Prognostic factors in ovarian cancer.

  1998cites this paper
• Histopathology and molecular biology of ovarian epithelial tumors.

  1998cites this paper
• Coexpression of the HER-2 Gene Product, pl85HER-2, and Epidermal Growth Factor Receptor, pl70EGF-R, on Epithelial Ovarian Cancers and Normal Tissues

  1998cites this paper
• Human ovarian cancer of the surface epithelium.

  1997cites this paper
• p53 alterations are predictive of chemoresistance and aggressiveness in ovarian carcinomas: a molecular and immunohistochemical study.

  1997cites this paper
• Immunohistochemical assessment of proliferation markers and altered gene expression in archival specimens of ovarian epithelial tumors.

  1997cites this paper
• Molecular genetic events in the development and progression of ovarian cancer in humans.

  1997cites this paper
• p53 and HER-2/neu overexpression in ovarian borderline tumors.

  1997cites this paper
• C-erbB-2, p53, N-ras expression in hepatocellular carcinoma

  1996cites this paper
• Expression of cell regulatory proteins in ovarian borderline tumors

  1996cites this paper
• Borderline ovarian tumors.

  1996cites this paper
• Prognostic significance of c-erB-2 mRNA in ovarian carcinoma.

  1996cites this paper
• Ovarian intraepithelial neoplasia and ovarian cancer.

  1996cites this paper
• The relationship between borderline ovarian tumors and epithelial ovarian carcinoma: epidemiologic, pathologic, and molecular aspects.

  1996cites this paper
• Oncogenes in gynecologic oncology.

  1996cites this paper
• Ovarian tumours of borderline malignancy: time for a reappraisal?

  1996cites this paper
• Oncogenes in Gynecologic Oncology

  1996cites this paper
• c‐erbB‐2 and p53 expression in fallopian tube carcinoma

  1995cites this paper
• Concurrent abnormal expression of erbB-2, myc and ras genes is associated with poor outcome of ovarian cancer patients.

  1995cites this paper
• Expression of neu Antigen in Normal Lactating and Prepartum Mammary Epithelial Cells

  1995cites this paper
• Epithelial-Mesenchymal Interactions in Cancer

  1995cites this paper
• Biomakers in the ovary

  1995cites this paper
• CSF-1 and its receptor in ovarian, endometrial and breast cancer.

  1995cites this paper
• Biomarkers in the ovary.

  1995cites this paper
• Overexpression of c‐erbB‐2 in epithelial ovarian cancer. Prognostic value and relationship with response to chemotherapy

  1995cites this paper
• [C-erbB-2 protein in ovarian epithelial cancer: correlation between expression in tumor tissue and blood levels].

  1995cites this paper
• Tumor-stromal cytokine interactions in ovarian neoplasms.

  1995cites this paper
• An evaluation of prognostic factors in advanced ovarian cancer.

  1995cites this paper
• Activation of c‐erbB‐2 and prognosis in ovarian carcinoma. Comparison with histologic type, grade, and stage

  1994cites this paper
• Prevalence and significance of HER‐2/neu expression in early epithelial ovarian cancer

  1994cites this paper
• Expression of c-erbB-2, c-myc, and c-ras oncoproteins, insulin-like growth factor receptor I, and epidermal growth factor receptor in ovarian carcinoma.

  1994cites this paper
• Clinical and laboratory directions for ovarian cancer research.

  1994cites this paper
• Frequent immunohistochemical detection of EGF supergene family members in ovarian carcinogenesis.

  1994cites this paper
• Molecular and clinical aspects of the Neu/ErbB-2 receptor tyrosine kinase.

  1994cites this paper
• Pathogenesis of Ovarian Cancers

  1994cites this paper
• Molecular biology and genetics of epithelial ovarian cancer.

  1994cites this paper
• Ovarian Carcinoma: Tumor- and Molecular Biology

  1993cites this paper
• Prognostic significance of HER‐2/neu expression in advanced epithelial ovarian cancer: A multivariate analysis

  1993cites this paper
• The expression of c-erbB-2 (HER-2/neu) oncogene in invasive ovarian malignancies

  1993cites this paper
• Expression of c-erbB-2, c-myc, and c-ras oncoproteins, insulin-like growth factor receptor

  year unknowncites this paper